Protalix BioTherapeutics (PLX) Depreciation & Amortization (CF) (2015 - 2026)
Protalix BioTherapeutics (PLX) posted quarterly Depreciation & Amortization (CF) of $404000.0 for Q1 2026, up 16.76% year-over-year from $346000.0 in Q1 2025, and up 4.39% quarter-over-quarter from $387000.0 in Q4 2025.
Protalix BioTherapeutics (PLX) Depreciation & Amortization (CF) (2015 - 2026) Analysis & Trends
Protalix BioTherapeutics' Depreciation & Amortization (CF) history runs 12 years deep, the most recent figure standing at $404000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 16.76% year-over-year to $404000.0; the TTM figure through Mar 2026 stood at $1.5 million (up 14.68% YoY), while the FY2025 annual figure was $1.5 million, up 12.35% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $404000.0, up from $387000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $404000.0 in Q1 2026, with the low at $268000.0 in Q2 2022.
- The 5-year median for Depreciation & Amortization (CF) is $319000.0 (2024), against an average of $321411.8.
- The sharpest annual moves came in 2022 and 2026: Depreciation & Amortization (CF) declined 6.94% in 2022, then climbed 16.76% in 2026.
- Protalix BioTherapeutics' Depreciation & Amortization (CF) stood at $289000.0 in 2022, then gained by 8.3% to $313000.0 in 2023, then rose by 6.71% to $334000.0 in 2024, then gained by 15.87% to $387000.0 in 2025, then climbed by 4.39% to $404000.0 in 2026.
- Business Quant data shows PLX's Depreciation & Amortization (CF) at $404000.0 in Q1 2026, $387000.0 in Q4 2025, and $372000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Protalix BioTherapeutics | 189.97 Mn | 149.31 Mn | 12.13 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 132,000.00 |
| Jun 30, 2026 | 132,000.00 |
| Mar 31, 2026 | 404,000.00 |
| Mar 31, 2026 | 404,000.00 |
| Dec 31, 2025 | 387,000.00 |
| Dec 31, 2025 | 387,000.00 |
| Sep 30, 2025 | 372,000.00 |
| Sep 30, 2025 | 372,000.00 |
| Jun 30, 2025 | 360,000.00 |
| Jun 30, 2025 | 360,000.00 |
| Mar 31, 2025 | 346,000.00 |
| Mar 31, 2025 | 346,000.00 |
| Dec 31, 2024 | 334,000.00 |
| Dec 31, 2024 | 334,000.00 |
| Sep 30, 2024 | 329,000.00 |
| Sep 30, 2024 | 329,000.00 |
| Jun 30, 2024 | 319,000.00 |
| Jun 30, 2024 | 319,000.00 |
| Mar 31, 2024 | 322,000.00 |
| Mar 31, 2024 | 322,000.00 |